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Introduction: We assessed the profile and frequency of malignancy subtypes in a large single-centre UK cohort for
patients with scleroderma (systemic sclerosis; SSc). We evaluated the cancer risk among SSc patients with different
antibody reactivities and explored the temporal association of cancer with the duration between SSc onset and
cancer diagnosis.
Methods: We conducted a retrospective study of a well-characterised cohort of SSc patients attending a large
tertiary referral centre, with clinical data collected from our clinical database and by review of patient records. We
evaluated development of all cancers in this cohort, and comparison was assessed with the SSc cohort without
cancer. The effect of demographics and clinical details, including antibody reactivities, were explored to find
associations relevant to the risk for development of cancer in SSc patients.
Results: Among 2,177 patients with SSc, 7.1% had a history of cancer, 26% were positive for anticentromere antibodies
(ACAs), 18.2% were positive for anti-Scl-70 antibodies and 26.6% were positive for anti-RNA polymerase III (anti-RNAP)
antibody. The major malignancy cancer subtypes were breast (42.2%), haematological (12.3%), gastrointestinal (11.0%)
and gynaecological (11.0%). The frequency of cancers among patients with RNAP (14.2%) was significantly increased
compared with those with anti-Scl-70 antibodies (6.3%) and ACAs (6.8%) (P < 0.0001 and P < 0.001, respectively). Among
the patients, who were diagnosed with cancer within 36 months of the clinical onset of SSc, there were more patients
with RNAP (55.3%) than those with other autoantibody specificities (ACA = 23.5%, P < 0.008; and anti-Scl-70 antibodies =
13.6%, P < 0.002, respectively). Breast cancers were temporally associated with onset of SSc among patients with
anti-RNAP, and SSc patients with anti-RNAP had a twofold increased hazard ratio for cancers compared to patients with
ACAs (P < 0.0001).
Conclusions: Our study independently confirms, in what is to the best of our knowledge the largest population
examined to date, that there is an association with cancer among SSc patients with anti-RNAP antibodies in close
temporal relationship to onset of SSc, which supports the paraneoplastic phenomenon in this subset of SSc cases.
An index of cautious suspicion should be maintained in these cases, and investigations for underlying malignancy
should be considered when clinically appropriate.Introduction
Systemic sclerosis (scleroderma, or SSc) is a hetero-
geneous, multisystem connective tissue disease that arises
as a consequence of a complex interplay of altered immu-
nologic processes involving vascular endothelial cell damage
and excessive activation of fibroblasts, culminating in skin
sclerosis and fibrotic changes of affected visceral organs.* Correspondence: c.denton@ucl.ac.uk
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distribution, and reproduction in any mediumThe association between SSc and increased cancer risk
has been reported in several case series, although this as-
sociation has not been consistently demonstrated across
all studies [1]. Researchers who have conducted recent
meta-analyses have reported increased numbers of solid
organ malignancies in SSc patients, including lung cancers
but not breast cancers. Investigators in other studies, how-
ever, have suggested that lung cancers are considered to
be common in patients with SSc [1-6]. The significant he-
terogeneity and variability in the cancer subtypes reported
in these studies may be a consequence of limited patienttral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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over, the actual role of SSc in the development of cancer
remains unclear. For example, it is debatable if SSc pa-
tients with severe interstitial lung disease have an in-
creased risk of developing lung cancer.
Few studies have examined the temporal relationship of
cancers to the onset of SSc, and the current literature that
links breast cancer to the onset of SSc remains contradict-
ory [7,8]. The role of autoantibodies and malignancies in
other autoimmune rheumatic diseases, however, has been
well-described, such as in large population-based studies
for inflammatory myositis. Anti-MJ/NXP2 and anti-p155/
140 antibodies have been described in cancer-associated
myositis. With regard to the latter, its high negative pre-
dictive value is potentially helpful to rule out the presence
of occult malignancy in patients with dermatomyositis
[9,10]. In contrast, only a few small case series have indi-
cated that the presence of hallmark SSc-specific anti-
bodies, anticentromere antibodies (ACAs) and anti-Scl-70
antibodies, correlates with cancer in SSc, but this finding
has not been consistently replicated in other studies. Shah
et al. recently reported that anti-RNA polymerase III
(anti-RNAP) antibodies may be associated with malig-
nancy in a small cohort of five patients with early-stage
SSc [8]. Airò et al. also described similar clustering of can-
cer associated with the onset of SSc in a small sample of
patients [7]. However, this observation has yet to be con-
firmed independently in a large cohort of patients. A bet-
ter understanding of this relationship between antibody
specificity and cancer in SSc is necessary to optimise
follow-up and surveillance of these patients.
We evaluated the frequency of cancer subgroups in a
large, single-centre UK cohort of patients with SSc. The
demographic and clinical characteristics of this cohort
were compared with matched cases without a history of
cancer. The risk of cancer was assessed across patients
with different autoantibody status, and the temporal re-
lationship between cancer diagnosis and clinical onset of
SSc was explored.
Methods
We conducted a retrospective study of patients attending
our centre. All of our patients met the classification cri-
teria of LeRoy as having limited cutaneous SSc (lcSSc) or
diffuse cutaneous SSc (dcSSc) [11-13]. Approval for this
study was obtained from the London Hampstead National
Research Ethics Services Committee, and all individuals
consented to use of their clinical and laboratory data for
the purposes of research.
To compare the patients with vs. those without cancer,
relevant demographic and clinical data related to cancer
subtypes and time of diagnosis were retrieved from the
Royal Free Hospital integrated patient records, and further
information was obtained from our large SSc researchdatabase, as well as, if appropriate, from referring physi-
cians or primary practitioners. Our database comprises in-
formation on patients with a median follow-up of
12.8 years (mean = 13.7 years; range = 0 to 52.5 years). All
SSc patients are seen in our research centre at least annu-
ally. The dates of the most recent visit were recorded for
all patients and were used for censoring in the analysis of
time to development of cancer.
SSc onset was defined by skin sclerosis or first SSc-
related internal organ manifestations other than Raynaud’s
phenomenon (RP). Patient demographics and key SSc
characteristics, including disease duration from the onset
of both first non-RP and first RP symptoms in addition to
modified Rodnan skin score were collected at baseline.
Clinical details pertaining to major internal organ involve-
ment for lung fibrosis, pulmonary arterial hypertension,
renal crisis and significant gastrointestinal (GI) involve-
ment were evaluated using consensus definitions as out-
lined in previously published studies [14].
Serum was routinely analysed in all SSc patients by indir-
ect immunofluorescence, counterimmunoelectrophoresis
and enzyme-linked immunosorbent assay to identify SSc-
specific autoantibodies (ACAs, anti-RNAP and anti-Scl-70)
at the first visit, and these analyses were repeated annually
during the clinic visit. This routine ensures complete data
capture for antibody reactivity and each patient has the
same antibody reactivity during the disease course in our
cohort [15,16]. This is consistent with published studies
that indicated that these antibodies are usually mutually ex-
clusive. Although the presence of these antibodies was not
studied prior to the onset of SSc in our cohort, their speci-
ficities remained constant throughout the disease course
[17]. The Hep2 immunofluorescence pattern was assessed
by an experienced clinical scientist to inform further
characterization of antibodies, including anti-RNAP anti-
bodies, as described previously [17,18].
The UK NHS National Care Records Service was used to
verify the vital status of patients with cancer who were
otherwise lost to follow-up. Statistical methods for contin-
gency tables (χ2 test or Fisher’s exact test) and time-to-
event data were employed. For proportions, 95% confidence
intervals (95% CI) were calculated according to Wilson’s
method. Differences between SSc patients with vs. without
a history of malignancy were assessed by means of Kaplan-
Meier curves and the logrank test. Multiple regression ana-
lysis (logistic and Cox) was undertaken to assess the impact
of autoantibody status on cancer risk (adjusted for age and
sex distribution). To include the development of cancers
prior to SSc onset in the analysis, these event times were
rescaled by subtraction of the smallest observed event time
(that is, −22 years). This step does not affect the character-
istics of semiparametric Cox regression or the logrank test.
For logistic regression, only the development of cancers
within 36 months of SSc onset (that is, before and after
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120 months around SSc onset were considered. Patients
for whom there was insufficient follow-up were excluded,
and event times beyond the preset limits were censored.
Similar logistic regression analysis was undertaken for
breast cancers. Hazard ratios (HRs), odds ratios (ORs) and
the corresponding 95% CIs were calculated. In order to
guard against type I error inflation due to multiple testing,
only P-values below 0.01 were considered statistically sig-
nificant [19]. For the purpose of data analysis, we de-
fined the onset of SSc as the date of appearance of the
first non-RP symptoms. Further analysis was under-
taken using the onset of RP as a proxy for the date of
SSc onset. Statistical analysis was performed using the
following software: SPSS (IBM, Armonk, NY, USA),
Stata (StataCorp, College Station, TX, USA; command
ci) and Excel (Microsoft, Redmond, WA, USA).
Results
Demographic and clinical characteristics of systemic
sclerosis patients with or without cancer
Among 2,177 patients with SSc who attended our centre
for management of their disease, 7.1% (n = 154) had can-
cer (Table 1). Within this cohort, 85.1% (131 of 154) were
females and 63.6% had lcSSc. Within this cohort, 26% had
ACAs, 18.2% were positive for anti-Scl-70 antibodies and
26.6% were positive for anti-RNAP antibodies. SSc pa-
tients with cancer (median age (±SD) = 53 ± 11.9 years)
were significantly older at the onset of SSc than those
without cancer (45 ± 14.1 years) (P = 0.023). Subanalysis
within antibody groups demonstrated that the age differ-
ence remained significant for patients with anti-RNAP
antibodies (56 ± 9.0 years vs. 45 ± 13.7 years, respectively;
P < 0.0001). SSc patients who had developed cancer had
a significantly higher frequency of anti-RNAP antibodies
than those without cancer (26.6% vs. 12.2%, respectively;
P < 0.0001). The remaining patients with cancer harboured
other antibody specificities, including antibodies against
nuclear ribonucleoproteins (nRNPs) (6.5%), Pm-Scl (5.8%),
Ro (5.8%) and Jo1 (0.65%). Among the SSc patients with
cancer, 5.8% were negative for antinuclear antibodies
(ANAs), and data were not available for five patients (two
patients each with breast and lung cancer and one patient
in the group of other cancers). Cancer developed after the
diagnosis of SSc in 54.5% of patients (84 of 154), and
30.5% (47 of 154) had been diagnosed with cancer before
visiting our centre with the diagnosis of SSc.
Associations between autoantibodies and cancer
The major malignancy subtypes in our cohort included
breast cancer in 42.2%, lung cancers in 10.4%, haemato-
logical cancers in 12.3% and GI or gynaecological in
11%. For a number of malignancies, there was a trend
towards increased frequency among patients with lcSSc.Detailed analysis of cancer subtypes was undertaken in
relation to the three major SSc-specific autoantibody
subgroups: ACA (n = 40), anti-Scl-70 (n = 28) and anti-
RNAP (n = 41) (Figure 1). In our cohort, breast cancer
was most frequently detected among patients with anti-
RNAP antibodies (46.3% (19 of 41)), followed by patients
with ACA antibodies (42.5% (17 of 40)) and anti-Scl-70
antibodies (35.7% (10 of 28)). The frequency of lung and
haematological cancers (17.9%) was equally distributed
in patients with anti-Scl-70 antibody. GI cancers oc-
curred in 20% of patients with ACA. There were signifi-
cantly more cancers among patients with anti-RNAP
antibodies (14.2% (41 of 288)) than in patients with anti-
Scl-70 antibodies (6.3% (28 of 444)) and ACA (6.8% (40 of
590)) (P < 0.0001 and P < 0.001, respectively).
Multivariable Cox regression analysis carried out to
explore the association of different autoantibodies and
cancer revealed that, compared to ACA (reference
group), the only antibody which significantly increased
the risk for cancer in SSc patients was the anti-RNAP
antibody (HR = 2.96, 95% CI = 1.85 to 4.73; P < 0.001).
For that reason, in subsequent analyses, anti-RNAP-
negative patients were grouped together. Thus we found
that, after being corrected for age and sex, anti-RNAP
positivity is associated with a significantly increased risk
of cancer, whether diagnosed either before or after SSc
onset (HR = 2.55, 95% CI = 1.75 to 3.74. P < 0.001)
(Table 2, row 2A). Older age was statistically significantly
associated with cancer risk (HR = 1.46, 95% CI = 1.28 to
1.67; P < 0.001). There was no association, however, be-
tween sex or SSc subsets and the development of cancer
in SSc patients. Subgroup analysis revealed that this as-
sociation remained significant when only cancers that
occurred after the onset of SSc were included (HR =
2.10, 95% CI = 1.27 to 3.48; P = 0.004) (Table 2, row 2B).
Kaplan-Meier estimates for the development of cancers
confirmed our findings that, compared to other hallmark
antibodies for SSc, anti-RNAP antibody–positive patients
have a significantly higher incidence of cancers (P < 0.0001
by logrank test) (Figure 2). From the onset of SSc through
20 years of follow-up, 195 patients with anti-RNAP anti-
bodies were lost to follow-up and a further 35 patients
were lost to follow-up over the following 20 years. For pa-
tients with anti-Scl-70 antibody, 328 patients were lost to
follow-up in the first 20 years of SSc and a further 56 pa-
tients were lost to follow-up in the following 20 years. For
patients with ACA, 370 patients were lost to follow-up in
the first 20 years after disease onset and another 103 pa-
tients were lost over the following 20 years. Within the
cancer cohort, 103 patients were still alive (66.9%, median
follow-up after cancer onset 6.4 years (25th to 75th percent-
ile: 3.3 to 12.3 years), and 48 had died (n = 21 (13.6%) as a
consequence of cancer, n = 4 (2.6%) due to SSc-related
causes and n = 24 (15.6%) due to unknown causes).
Table 1 Demographics and clinical features of overall cohort for patients with vs. without cancera
Characteristics Cancer subgroups
No cancer (n = 2,023) Total (N = 154) Breast (n = 65) Lung (n = 16) Haemato (n = 19) GI (n = 17) GU (n = 6) Gynae (n = 17) Skin (n = 6)
Sex
Female, n (%) 1,663 (82.2) 131 (85.1) 65 (100) 12 (75) 14 (73.7) 13 (76.5) 2 (33.3) 17 (100) 3 (50)
Male, n (%) 360 (17.8) 23 (14.9) NA 4 (25) 5 (26.3) 4 (23.5) 4 (66.7) NA 3 (50)
SSc/cancer onset
Median age (±SD) at
SSc onset, years
45 (±14.1) 53 (±11.9) 53 (±11.1) 47 (±19.5) 51.5 (±9.4) 53 (±11.4) 59 (±18.4) 53 (±23.7) 59.5 (±19.1)
IQR = 35 to 55 IQR = 43 to 58 IQR = 44 to 58 IQR = 41 to 54 IQR = 44 to 56 IQR = 45 to 60 IQR39 to 68 IQR = 35 to 57 IQR = 46 to 63
Cancer prior to SSc onset
(median ± SD), months
No cancer 39.5 (±81.6) 36 (±77.3) NA 109 (±88.2) 8.5 (±27.7) 25 (±74.4) 141 (±104.8) NA
IQR = 12 to 125 IQR = 11 to 114 IQR = 29 to 190 IQR = 1 to 48 IQR = 4 IQR = 25 to 243
Cancer after SSc onset,
(median ± SD), months
No cancer 119 (±95.3) 108 (±108.5) 125 (±93.8) 101 (±73.4) 168 (±90.6) 116.5 (±79.9) 137 (±91.9) 62 (±55.5)
IQR = 41 to 185 IQR = 25 to 209 IQR = 71 to 200 IQR = 20 to 161 IQR = 119 to 233 IQR = 60 IQR = 20 to 194 IQR = 23 to 125
SSc subsets
dcSSc, n (%) 657 (32.5) 53 (34.4) 22 (33.8) 5 (31.3) 8 (42.1) 4 (23.5) 2 (33.3) 4 (23.5) 3 (50)
lcSSc, n (%) 1,260 (62.3) 98 (63.6) 42 (64.6) 11 (68.8) 11 (57.9) 12 (70.6) 3 (50) 13 (76.5) 3 (50)
Missing cases, n (%) 106 (5.2) 3 (1.9) 1 (1.5) 0 (0) 0 (0) 1 (5.9) 1 (16.7) 0 (0) 0 (0)
SSc autoantibody status
ACA, n (%) 550 (27.2) 40 (26) 17 (26.2) 2 (12.5) 4 (21.1) 8 (47.1) 1 (16.7) 6 (35.3) 1 (16.7)
Scl to 70, n (%) 416 (20.6) 28 (18.2) 10 (15.4) 5 (31.3) 5 (26.3) 1 (5.9) 1 (16.7) 4 (23.5) 1 (16.7)
RNAP, n (%) 247 (12.2) 41 (26.6) 19 (29.2) 4 (25) 5 (26.3) 3 (17.6) 2 (33.3) 3 (17.6) 3 (50)
Others, n (%) 515 (25.4) 31 (20) 13 (19.9) 3 (18.9) 4 (21) 3 (17.6) 1 (16.7) 4 (23.6) 1 (16.7)
ANA-negative, n (%) 75 (3.7) 9 (5.8) 4 (6.2) 0 (0) 1 (5.3) 2 (11.8) 1 (16.7) 0 (0) 0 (0)
Missing cases, n (%) 220 (10.9) 5 (3.2) 2 (3.1) 2 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Organ involvementb
Lung fibrosis, n (%) NA 52 (33.8) 24 (36.9) 8 (50) 6 (31.6) 4 (23.5) 3 (33.3) 2 (11.8) 2 (33.3)
PAH, n (%) NA 27 (17.5) 15 (23.1) 1 (6.3) 3 (15.8) 3 (17.6) 0 (0) 2 (11.8) 1 (16.7)
GI, n (%) NA 85 (55.2) 35 (53.8) 9 (56.3) 12 (63.2) 9 (52.9) 1 (16.7) 10 (58.8) 3 (50)
SRC, n (%) NA 16 (10.4) 4 (6.2) 1 (6.3) 2 (10.5) 4 (23.5) 1 (16.7) 2 (11.8) 0 (0)
aACA, Anticentromere antibody; ANA, Antinuclear antibody; dcSSc, Diffuse cutaneous systemic sclerosis; GI, Gastrointestinal; GU, Genitourinary; Gynae, Gynaecological; Haemato, Haematological; IQR, Interquartile range;
lcSSc, Limited cutaneous systemic sclerosis; NA, Not applicable; PAH, Pulmonary arterial hypertension; RNAP, RNA polymerase III; SRC, Scleroderma renal crisis; SSc, Systemic sclerosis. Cohort sample populations
comprised 154 SSc patients with cancer and 2,023 SSc patients without cancer. bExtent and pattern of organ involvement is defined in the Methods section.
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Figure 1 Graph showing the frequency of different cancer subgroups for each major systemic sclerosis-specific autoantibody subtype
(anticentromere, anti-Scl-70 and anti-RNA polymerase III antibodies). ACA, Anticentromere antibody; GIT, Gastrointestinal; GU, Genitourinary;
Gynae, Gynaecological; Haemato, Haematological; RNAP, RNA polymerase III. Other cancers include thyroid and brain.
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cancer onset within antibody subgroups
Significantly more patients who harboured anti-RNAP
antibodies (55.3%, 21 of 38) were diagnosed with cancer
within 36 months of SSc onset compared to those with
ACA (21.2%, 7 of 33; P < 0.004) and those with anti-Table 2 Multivariable Cox and logistic regression analyses to
antibodies and development of cancersa
Variable Frequency (n)
2A: Multivariable Cox regression analysis
Age (per 10 years) 1,740 valid
Male vs. female 299 vs. 1,441
RNAP+ vs. RNAP− 268 vs. 1,472
2B: Multivariable Cox regression analysis
Age (per 10 years) 1,694 valid
Male vs. female 294 vs. 1,401
RNAP+ vs. RNAP− 250 vs. 1,445
2C: Logistic regression analysis
Age (per 10 years) 1,617 valid
Male vs. female 265 vs. 1,352
RNAP+ vs. RNAP− 249 vs. 1,368
aCI, Confidence interval; RNAP+, positivity for anti-RNA polymerase III antibodies; RN
other antibodies. These analyses include all events (row 2A) with total frequency N
sclerosis onset (row 2B) with total frequency N = 2,177, 483 cases dropped, 83 even
(row 2C) with total frequency N = 1,623, 6 missing cases, 42 events.Scl-70 antibodies (13.6%, 3 of 22; P < 0.002). Patients
with anti-RNAP antibodies had nearly six times higher
odds of developing cancer within 36 months compared to
those without anti-RNAP antibodies (OR = 5.83, 95% CI =
3.1 to 10.9; P < 0.001) (Table 2, row 2C). No significant as-
sociation was observed between anti-RNAP antibodies andevaluate the association between anti-RNA polymerase III
Hazard/Odds ratio 95% CI P-value
1.46 1.28 to 1.67 <0.001
0.83 0.50 to 1.39 0.487
2.55 1.75 to 3.74 <0.001
1.43 1.21 to 1.70 <0.001
0.93 0.53 to 1.80 0.931
2.10 1.27 to 3.48 0.004
1.63 1.27 to 2.09 <0.001
0.73 0.28 to 1.90 0.514
5.83 3.11 to 10.92 <0.001
AP−, anticentromere antibodies, anti-Scl-70, antinuclear antibody-negative and
= 2,177, 437 cases dropped, 128 events, 1,612 censored; events post-systemic
ts, 1,611 censored; and for events within 36 months of systemic sclerosis onset
Figure 2 Kaplan-Meier analysis shows three different curves for each patient group with the designated autoantibody subset.
Events (defined as diagnosis of cancer) correspond to step-downs, and censored observations (defined as most recent follow-up visit) are identified
by tick marks. The plot shows a significant difference (P < 0.0001) between the number and timing of events between anti-RNA polymerase III
(anti-RNAP)–positive patients and anticentromere antibody (ACA)– or Scl-70-positive patients. The dotted vertical line (designated as time 0) represents
the clinical onset of systemic sclerosis (SSc). Within the 36-month period prior to the onset of SSc, 13 patients with the anti-RNAP antibody, compared
with only 2 patients with ACA, were diagnosed with cancer. Number at risk, number and percentage loss to follow-up are represented for the intervals
between SSc onset and the 20- and 40-year periods.
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SSc onset (P = 0.65) and between 60 and 120 months prior
to and after SSc onset (P = 0.02). The temporal rela-
tionship of cancers for all three major antibody reac-
tivities and anti-RNAP antibody are illustrated in
Figure 3A. Most cancers occurred after the onset of
SSc. The frequency was highest at the onset of SSc,
and this was particularly prominent among patients
with anti-RNAP antibody (Figure 3B).
Temporal association between systemic sclerosis and
breast cancer
Patients with anti-RNAP antibodies were 19 times more
likely to develop breast cancer within 36 months com-
pared to those with ACA antibodies (95% CI = 4.34 to
91.94; P < 0.001). No significant association was observed
between anti-RNAP antibodies and the development of
breast cancers 36 to 60 months prior to and after SSc on-
set (P = 0.996) and 60 to 120 months prior and after SSc
onset (P = 0.07). Similar to the pattern observed for all
cancers, the increased frequency of breast cancer ap-
peared to cluster around the onset of SSc (Figure 3C),
with its highest peak being reached just before the onset
of SSc for those with anti-RNAP antibodies (Figure 3D).
This pattern of cancer distribution was not observed inassociation with ACA or anti-Scl-70 antibodies (data not
shown). In addition, age had an impact on the risk for
breast cancer. The risk was doubled for each decade of life
(OR = 2.14, 95% CI = 1.35 to 3.40; P < 0.001). No significant
association was observed for the other two antibodies.
Analysis using onset of Raynaud’s phenomenon as onset
of systemic sclerosis
The duration of RP prior to progression to SSc was consi-
dered as proxy for SSc onset and included in the Cox re-
gression analysis. Significantly more patients who harboured
anti-RNAP antibodies (43.8%, 14 of 32) were diagnosed with
cancer within 36 months of RP onset compared to those
with ACA (13.3%, 4 of 30; P= 0.012) and those with anti-
Scl-70 antibodies (5.3%, 1 of 19; P= 0.004). In addition, Cox
proportional hazards regression analysis with RP onset used
as a proxy for SSc onset demonstrated that the HR for
development of cancer remained similar (HR = 2.86, 95%
CI = 1.54 to 5.32; P= 0.001) in those with anti-RNAP
antibodies compared to those with the ACA subtype.
Discussion
There is emerging evidence from recent case series and
epidemiological studies that SSc is associated with an in-
creased risk for various malignancies [1,20]. In this large
Figure 3 Graphs illustrating temporal relationship of cancers (including all cancers and breast cancers) for all three major antibody
reactivities and anti-RNA polymerase III antibody. (A) Frequency of all cancers (n = 129) across all three major antibody reactivities (anti-Scl-70,
anticentromere and anti-RNA polymerase III (RNAP) antibodies). (B) Frequency of all cancers for anti-RNAP antibody alone (n = 38). (C) Frequency of
breast cancers (n = 60) for all three major antibody reactivities. (D) Frequency of breast cancers (n = 19) for anti-RNAP antibody.
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that, compared with patients without cancer (N = 2,023),
SSc patients with cancer (N = 154) were more frequently
positive for anti-RNAP antibodies than the other hallmark
SSc-specific antibodies, ACA or anti-Scl-70 antibodies.
This study confirms that positivity for anti-RNAP anti-
bodies is associated with at least a twofold increased HR
for cancers that occurred before or after onset of SSc com-
pared to those without anti-RNAP antibodies. The associ-
ation remained significant for anti-RNAP antibodies and
the development of cancers that occurred after the onset
of SSc. In contrast, no significant differences in cancer fre-
quency were demonstrated across disease subsets or be-
tween the sexes. Ethnicity data were not available, so this
factor could not be considered in the analyses.
Importantly, the results of our present study demonstrate
that positivity for anti-RNAP antibodies conferred sixfold
higher odds for developing cancer within 36 months of SSc
onset compared to those without this antibody, highlighting
the close temporal association in this subgroup. This result
supports the observation in an earlier study by Shah et al.,
who found that patients with anti-RNAP antibodies devel-
oped SSc within 2 years of cancer onset in a smaller cohort
of 23 patients [8]. Airò et al. also reported a clustering of
cancers with SSc onset in a small sample of patients with
anti-RNAP antibodies [7]. In our present study, thistemporal relationship was noted in particular among SSc
patients with breast cancer, supporting the observation re-
cently reported by Launay et al. [21]. The temporal rela-
tionship between cancer and SSc reported herein is similar
to that of adenocarcinomas in dermatomyositis patients,
and this association also extends, albeit with lower risk, to
patients with two other autoimmune rheumatic diseases:
polymyositis and systemic lupus erythematosus [22-24]. In
this regard, this association suggests that the presentation
of malignancy and the onset of SSc may be mechanistically
linked and that the confluence of SSc and cancer also indi-
cates that some cases of SSc might represent a paraneoplas-
tic syndrome in which the immune system is responding to
cancer.
Shah et al. also detected enhanced expression of nucle-
olar RNAP exclusively in the tumoural tissues of SSc pa-
tients with anti-RNAP antibodies in whom there was a
close temporal relationship between the onset of cancer
and SSc [8]. RNAP is critical for regulation of sustained
cellular protein synthesis and is therefore a fundamental
determinant of normal cellular growth. Recently, strong
evidence has implicated abnormal RNAP activity in cancer
cells from breast and lung carcinomas [25] and in fibro-
blasts transformed by Simian virus 40 or other polyomavi-
rus [26,27]. It is postulated that repression of tumour
suppressors p53 and retinoblastoma [28] and/or activation
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RNAP activity in malignancy. However, the biological basis
for an association between specific autoantibody subtypes
against NRAP and malignancy in the context of SSc is un-
clear. The presence of anti-RNAP antibody may initiate an
antitumour immune response that, in the appropriate set-
ting, may cross-react against specific host tissue, resulting
in target tissue damage. Proof supporting this hypothesis
may provide some insight into the fundamental mechanis-
tic aspects of pathogenesis and highlight the cancer–auto-
immunity interface in this particular subset of SSc as a
paraneoplastic syndrome.
It is disputed whether SSc onset should be defined from
the development of RP or from the first non-RP symptoms
[30]. For that reason, the duration of RP prior to SSc onset
was considered, and repeat analysis indicated that the asso-
ciation between anti-RNAP antibodies and malignancy
remained significant. This finding in our study is not sur-
prising, given that we have previously shown in an inde-
pendent cohort that the duration of antecedent RP differs
substantially between SSc-specific antibodies with the
shortest interval between onset of RP and first non-RP fea-
tures for patients with anti-RNAP antibodies (average of
1.7 years) and longest for ACA-positive patients (average of
10.8 years) [31].
Different types of cancers have been reported among SSc
patients, including cancers that are common in the general
population, such as breast and lung cancers. In agreement
with this, the leading cancer subtypes in our patient cohort
were breast cancer (42.2%), followed by haematological
malignancies (12.3%), GI and gynaecological cancers (11%
each), and lung cancer (10.4%). Other authors, however,
have reported lung cancer [32-35] and GI malignancies
[36,37] as the most common cancer subtypes associated
with SSc. The variability in the reported incidence of malig-
nancies and common cancer subtypes associated with SSc
in these other studies might be due to differences in study
design, case ascertainment, cancer prevalence in the general
population studied, ethnicity and gender distribution. These
factors may account for the high standardized incidence ra-
tios reported for some cancer subtypes, including lung can-
cer. The magnitude of absolute risk for these individual
cancers is likely to be low [32,38,39]. For example, the re-
cent meta-analysis reported by Bonifazi et al. [20] included
a large number of patients from a heterogeneous cohort
and case–control retrospective studies, and the authors did
not find an increased risk of breast cancers, although the
results of some other studies have implicated a strong tem-
poral clustering of breast cancer with SSc onset [40,41].
The association of breast cancer with SSc may be attrib-
uted to the potential role of sex hormones in disease de-
velopment of SSc and breast cancer. Increased levels of
prolactin and low dehydroepiandrosterone in patients with
SSc [42,43] and breast cancer [44] lend further support tothis association. It is also noteworthy that the heterogen-
eity of SSc may preclude a definitive conclusion regarding
the association of SSc and cancer.
A variety of potential reasons have been postulated for
the apparent association of SSc and cancer. These include
shared risk factors such as gender distribution, exposure to
immunosuppressive drugs and possible shared genetic
backgrounds of both disorders. The precise pathogenic
mechanisms that cause and maintain an autoimmune re-
sponse in patients with cancer has not been fully elucidated.
Autoimmunity in cancer may occur as a consequence of
an abnormal self-antigen expression and/or mutated
antigens, as well as of tumour-derived biological sub-
stances produced by cancer cells. In addition, the conse-
quences of chronic inflammation and fibrotic processes
may damage tissue, cells and DNA, leading to altered
immune responses and the development of malignant
transformation, triggering the development of lung cancer
or cutaneous malignancies. Dysregulation of molecular sig-
nalling pathways involving transforming growth factor β
and SMAD pathways have been reported to induce fibrosis
and also tumourigenesis [45]. In a recent study, the investi-
gators suggested that both DNA methylation and histone
modification may contribute to excessive synthesis of extra-
cellular matrix proteins in SSc and that an imbalance may
lead to autoimmune diseases and also cancer [46].
Conclusions
Our study, which to the best of our knowledge is the lar-
gest to date addressing the temporal association between
the autoantibody subtypes and cancer in SSc, provides
independent confirmation to recent studies that SSc pa-
tients who harbour anti-RNAP antibodies have an in-
creased risk of cancer within a short interval of the
clinical onset of SSc. Increased awareness among physi-
cians is required to institute appropriate investigations
where necessary. Further studies to evaluate the bio-
logical link between anti-RNAP antibodies and malig-
nancy in SSc should be undertaken in future studies.
Our data add to the early observation, that SSc may be a
paraneoplastic syndrome in some cases. Currently, there
are no data to support the cost-effectiveness of screening
for underlying malignancy in patients with early onset
SSc with anti-RNAP antibodies. However, it may be ap-
propriate to screen individuals at high risk and those
who fail to respond to therapy.
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